Pharvaris N.V. PHVS 深 滬
等待開盤 11-01 09:30:00 美东时间
22.25
+0.010
+0.04%
華盛通- 最 高22.40
- 今 開22.26
- 成交量 7.27万股
- 最 低 21.76
- 昨 收 22.24
- 總市值 12.12亿
- 52周最高 26.33
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 11.51
- 委 比 77.78%
- 總股本 5449.31万
- 歷史最高 42.86
- 量 比 0.37
- 振 幅 2.88%
- 歷史最低 1.77
- 每 手 1
- 風險率 3.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting
Pharvaris, a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists, announced the acceptance of two abstracts for oral presentation and six for poster presentation at the ACAAI 2025 Annual Scientific Meeting in Orlando, FL. The oral presentations will discuss clinical validation of a kinin biomarker assay and long-term safety/efficacy of oral deucrictibant for HAE prophylaxis. Poster presentations will cover topi...
10-23 10:50
美股大行评级 | 贝莱德、花旗、摩根大通、富国银行均获上调目标价！汇丰上调超微公司目标价升至310美元
今日重点评级关注：Roth Capital：维持Cingulate"买入"评级，目标价从10美元升至17美元；JMP证券：维持BioCryst Pharma"跑赢大市"评级，目标价从17美元升至27美元
10-16 10:43
美股大行评级 | 潜在涨幅334.0%！HC Wainwright & Co.上调Inventiva目标价至24美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Inventiva"买入"评级，目标价从20美元升至24美元；摩根大通：维持BioMarin Pharmaceutical"超配"评级，目标价从116美元升至119美元
10-10 11:36
B of A Securities Upgrades Pharvaris to Neutral, Raises Price Target to $27
B of A Securities analyst Tazeen Ahmad upgrades Pharvaris (NASDAQ:PHVS) from Underperform to Neutral and raises the price target from $16 to $27.
10-09 18:55
Pharvaris Secures Registration Rights Agreement with General Atlantic
Pharvaris ( ($PHVS) ) just unveiled an update. On September 2, 2025, Pharvaris ...
09-09 05:17
JMP Securities Maintains Market Outperform on Pharvaris, Lowers Price Target to $52
JMP Securities analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and lowers the price target from $55 to $52.
08-13 22:21
Pharvaris Q2 EPS $(0.94) Misses $(0.87) Estimate
Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.94) per share which missed the analyst consensus estimate of $(0.87) by 8.05 percent. This is a 59.32 percent decrease over losses of $(0.59) per share from the
08-13 04:41
Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update
Pharvaris reported progress on its late-stage clinical trials for deucrictibant, including RAPIDe-3 (on-demand treatment for HAE attacks, with topline results expected in 4Q2025), CHAPTER-3 (prophylaxis for HAE attacks, with results in 2H2026), and CREAATE (treatment for AAE-C1INH attacks, set to begin by year-end 2025). The company strengthened its financial position with a $201 million public offering, extending its cash runway into 1H2027. Pha...
08-12 20:05
Pharvaris prices $175M securities offering
Pharvaris (NASDAQ:PHVS) priced an underwritten offering of 8.25 million shares at $20 each and 500,000 pre-funded warrants at $19.99 each, raising around $175 million in gross proceeds. The company al...
07-23 13:20
Pharvaris shares are trading lower after the company announced a $150 million proposed public offering.
Pharvaris shares are trading lower after the company announced a $150 million p...
07-23 04:24
